US Residents Only


Dosing and administration of Zokinvy®

Getting patients with progeria or processing-deficient progeroid laminopathies (PDPL) onto an appropriate dosage of Zokinvy matters.


Zokinvy is available in 50-mg and 75-mg capsules, which allows for flexible administration between starting and final dose. Recommended dosing is capsules twice daily with food.1

Recommended dosage of Zokinvy is based on body surface area (BSA)
Starting dosage of Zokinvy

For patients with a BSA ≥ 0.39 m2, the starting dosage is 115 mg/m2 twice daily with morning and evening meals. An appropriate dosage strength of Zokinvy is not available for patients with a BSA below 0.39 m2.1

After 4 months of treatment

Increase the dosage to 150 mg/m2 twice daily. Round all total daily doses to the nearest 25-mg increment.1

If a dose is missed
  • Instruct the patient to take the dose as soon as possible, with food, up to 8 hours prior to the next scheduled dose.1
  • If fewer than 8 hours remain before the next scheduled dose, skip the missed dose and resume taking Zokinvy at the next scheduled dose.1
Download more details on dosing

Information regarding recommended dosages of 115 mg/m2 and 150 mg/m2 is included.

Managing progeria and PDPL can be complicated. With Zokinvy, you have options.

Administration options:

Depending on the patient’s ability to swallow, Zokinvy can be taken alone or mixed with Ora-Blend SF®, Ora-Plus®, orange juice, or applesauce. Do not mix with any juice containing grapefruit or Seville oranges. Ensure that the mixture is taken within approximately 10 minutes of mixing.1

Adverse reactions:

For unmanageable adverse reactions, dosing of Zokinvy can be reduced to the starting dosage (115 mg/m² twice daily).1

Use with loperamide:

Loperamide is contraindicated in patients less than 2 years of age. When Zokinvy is coadministered with loperamide, do not exceed loperamide 1 mg once daily when first coadministered. Slowly increase loperamide dosage with caution in accordance with its approved product labeling.1

Use with midazolam:

Discontinue Zokinvy for 10 to 14 days before and 2 days after administration of midazolam.1


Starting and staying on Zokinvy matters. Enroll your patient today.

Eiger OneCare helps patients and their caregivers with access to a dedicated, specialized team. Each member of this team is focused on the care and needs of patients with progeria or PDPL. Download an enrollment form to start the process.

Enroll Now



ZOKINVY is contraindicated in patients taking:

  • Strong or moderate CYP3A inhibitors or inducers
  • Midazolam
  • Lovastatin, simvastatin, and atorvastatin


ZOKINVY is indicated in adult and pediatric patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above:

  • To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS)
  • For the treatment of processing-deficient